Literature DB >> 28445461

Tumour ischaemia by interferon-γ resembles physiological blood vessel regression.

Thomas Kammertoens1,2, Christian Friese1,2, Ainhoa Arina3, Christian Idel4, Dana Briesemeister1,2, Michael Rothe1,2, Andranik Ivanov5,6, Anna Szymborska2, Giannino Patone2, Severine Kunz2, Daniel Sommermeyer2, Boris Engels2, Matthias Leisegang1,2,5, Ana Textor1,2, Hans Joerg Fehling7, Marcus Fruttiger8, Michael Lohoff9, Andreas Herrmann10, Hua Yu10, Ralph Weichselbaum3, Wolfgang Uckert2,5, Norbert Hübner2,6,11, Holger Gerhardt2,5,11, Dieter Beule2,5, Hans Schreiber1,4,5, Thomas Blankenstein1,2,5.   

Abstract

The relative contribution of the effector molecules produced by T cells to tumour rejection is unclear, but interferon-γ (IFNγ) is critical in most of the analysed models. Although IFNγ can impede tumour growth by acting directly on cancer cells, it must also act on the tumour stroma for effective rejection of large, established tumours. However, which stroma cells respond to IFNγ and by which mechanism IFNγ contributes to tumour rejection through stromal targeting have remained unknown. Here we use a model of IFNγ induction and an IFNγ-GFP fusion protein in large, vascularized tumours growing in mice that express the IFNγ receptor exclusively in defined cell types. Responsiveness to IFNγ by myeloid cells and other haematopoietic cells, including T cells or fibroblasts, was not sufficient for IFNγ-induced tumour regression, whereas responsiveness of endothelial cells to IFNγ was necessary and sufficient. Intravital microscopy revealed IFNγ-induced regression of the tumour vasculature, resulting in arrest of blood flow and subsequent collapse of tumours, similar to non-haemorrhagic necrosis in ischaemia and unlike haemorrhagic necrosis induced by tumour necrosis factor. The early events of IFNγ-induced tumour ischaemia resemble non-apoptotic blood vessel regression during development, wound healing or IFNγ-mediated, pregnancy-induced remodelling of uterine arteries. A better mechanistic understanding of how solid tumours are rejected may aid the design of more effective protocols for adoptive T-cell therapy.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28445461      PMCID: PMC5567674          DOI: 10.1038/nature22311

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  41 in total

1.  Interferon-gamma elicits arteriosclerosis in the absence of leukocytes.

Authors:  G Tellides; D A Tereb; N C Kirkiles-Smith; R W Kim; J H Wilson; J S Schechner; M I Lorber; J S Pober
Journal:  Nature       Date:  2000-01-13       Impact factor: 49.962

2.  Faithful activation of an extra-bright red fluorescent protein in "knock-in" Cre-reporter mice ideally suited for lineage tracing studies.

Authors:  Hervé Luche; Odile Weber; Tata Nageswara Rao; Carmen Blum; Hans Jörg Fehling
Journal:  Eur J Immunol       Date:  2007-01       Impact factor: 5.532

3.  Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins.

Authors:  A D Luster; J C Unkeless; J V Ravetch
Journal:  Nature       Date:  1985 Jun 20-26       Impact factor: 49.962

4.  Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance.

Authors:  Gerald Willimsky; Thomas Blankenstein
Journal:  Nature       Date:  2005-09-01       Impact factor: 49.962

Review 5.  Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments.

Authors:  Karin Schreiber; Donald A Rowley; Gert Riethmüller; Hans Schreiber
Journal:  Hematol Oncol Clin North Am       Date:  2006-06       Impact factor: 3.722

6.  Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function.

Authors:  H W Mittrücker; T Matsuyama; A Grossman; T M Kündig; J Potter; A Shahinian; A Wakeham; B Patterson; P S Ohashi; T W Mak
Journal:  Science       Date:  1997-01-24       Impact factor: 47.728

7.  Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer.

Authors:  Kathleen Anders; Christian Buschow; Andreas Herrmann; Ana Milojkovic; Christoph Loddenkemper; Thomas Kammertoens; Peter Daniel; Hua Yu; Jehad Charo; Thomas Blankenstein
Journal:  Cancer Cell       Date:  2011-12-13       Impact factor: 31.743

8.  Ovarian angiogenesis. Phenotypic characterization of endothelial cells in a physiological model of blood vessel growth and regression.

Authors:  H G Augustin; K Braun; I Telemenakis; U Modlich; W Kuhn
Journal:  Am J Pathol       Date:  1995-08       Impact factor: 4.307

9.  IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers.

Authors:  Bin Zhang; Theodore Karrison; Donald A Rowley; Hans Schreiber
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

10.  IRF4 is a novel mediator for neuronal survival in ischaemic stroke.

Authors:  S Guo; Z-Z Li; D-S Jiang; Y Y Lu; Y Liu; L Gao; S-M Zhang; H Lei; L-H Zhu; X-D Zhang; D-P Liu; H Li
Journal:  Cell Death Differ       Date:  2014-02-07       Impact factor: 15.828

View more
  100 in total

1.  CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade.

Authors:  Yuji Sato; Jennifer K Bolzenius; Abdallah M Eteleeb; Xinming Su; Christopher A Maher; Jennifer K Sehn; Vivek K Arora
Journal:  JCI Insight       Date:  2018-12-06

Review 2.  Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways.

Authors:  Xue Bai; David E Fisher; Keith T Flaherty
Journal:  Nat Rev Clin Oncol       Date:  2019-09       Impact factor: 66.675

3.  Alteration of Tumor Metabolism by CD4+ T Cells Leads to TNF-α-Dependent Intensification of Oxidative Stress and Tumor Cell Death.

Authors:  Tsadik Habtetsion; Zhi-Chun Ding; Wenhu Pi; Tao Li; Chunwan Lu; Tingting Chen; Caixia Xi; Helena Spartz; Kebin Liu; Zhonglin Hao; Nahid Mivechi; Yuqing Huo; Bruce R Blazar; David H Munn; Gang Zhou
Journal:  Cell Metab       Date:  2018-06-07       Impact factor: 27.287

Review 4.  Microenvironmental regulation of tumour angiogenesis.

Authors:  Michele De Palma; Daniela Biziato; Tatiana V Petrova
Journal:  Nat Rev Cancer       Date:  2017-07-14       Impact factor: 60.716

5.  Endosteal vessel integrity: a new therapeutic goal in acute myeloid leukemia?

Authors:  Paolo Bernasconi; Oscar Borsani
Journal:  Stem Cell Investig       Date:  2018-10-22

Review 6.  IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy.

Authors:  Lionel B Ivashkiv
Journal:  Nat Rev Immunol       Date:  2018-09       Impact factor: 53.106

7.  CD4 T-cells regulate angiogenesis and myogenesis.

Authors:  Brian J Kwee; Erica Budina; Alexander J Najibi; David J Mooney
Journal:  Biomaterials       Date:  2018-06-06       Impact factor: 12.479

8.  Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade.

Authors:  Chien-Chun Steven Pai; John T Huang; Xiaoqing Lu; Donald M Simons; Chanhyuk Park; Anthony Chang; Whitney Tamaki; Eric Liu; Kole T Roybal; Jane Seagal; Mingyi Chen; Katsunobu Hagihara; Xiao X Wei; Michel DuPage; Serena S Kwek; David Y Oh; Adil Daud; Katy K Tsai; Clint Wu; Li Zhang; Marcella Fasso; Ravi Sachidanandam; Anitha Jayaprakash; Ingrid Lin; Amy-Jo Casbon; Gillian A Kinsbury; Lawrence Fong
Journal:  Immunity       Date:  2019-02-05       Impact factor: 31.745

9.  Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.

Authors:  Juliane Gust; Kevin A Hay; Laïla-Aïcha Hanafi; Daniel Li; David Myerson; Luis F Gonzalez-Cuyar; Cecilia Yeung; W Conrad Liles; Mark Wurfel; Jose A Lopez; Junmei Chen; Dominic Chung; Susanna Harju-Baker; Tahsin Özpolat; Kathleen R Fink; Stanley R Riddell; David G Maloney; Cameron J Turtle
Journal:  Cancer Discov       Date:  2017-10-12       Impact factor: 39.397

Review 10.  Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa.

Authors:  Kabir A Khan; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2018-02-13       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.